BioCentury
ARTICLE | Company News

Teva, Actavis plc neurology, generics news

June 9, 2014 7:00 AM UTC

Teva's Cephalon Inc. subsidiary will grant Actavis rights to market generic versions of sleep disorder drug Nuvigil armodafinil to settle all patent litigation between the companies. Actavis can market 100 and 200 mg strengths of generic Nuvigil in the U.S. beginning on June 1, 2016, or earlier under undisclosed circumstances. Actavis may also market generic versions of 50, 150 and 250 mg strengths of generic Nuvigil 180 days after the initial launch of generic versions of those dosage strengths. Actavis said that other details of the settlement were not disclosed. ...